Date: <u>5/10/2023</u>
Your Name: Daniel Sentana-Lledo
Manuscript Title: EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approved
targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Manuscript number (if known): TLCR-23-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _XNone	36 months
3	Royalties or licenses	_XNone	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
Ü	testimony	_X_None	
	•		
7	Support for attending meetings and/or travel	_XNone	
	G ,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
_			
12	Receipt of equipment,	_XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No COIs			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>5/10/2023</u>
Your Name: Emmeline Academia
Manuscript Title: EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approve
targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Manuscript number (if known): TLCR-23-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _XNone	36 months
3	Royalties or licenses	_XNone	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
Ü	testimony	_X_None	
	•		
7	Support for attending meetings and/or travel	_XNone	
	G ,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
_			
12	Receipt of equipment,	_XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No COIs			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>5/10/2023</u>
Your Name: Hollis Viray
Manuscript Title: EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approved
targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Manuscript number (if known): TLCR-23-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _XNone	36 months
3	Royalties or licenses	_XNone	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
Ü	testimony	_X_None	
	•		
7	Support for attending meetings and/or travel	_XNone	
	G ,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
_			
12	Receipt of equipment,	_XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No COIs			

Please place an "X" next to the following statement to indicate your agreement:

Date:	5/10/2023
Your Name:	Deepa Rangachari
Manuscript Title:	EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Manuscript Number (if known):	TLCR-23-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None Time frame: past 36 month	Click the tab key to add additional rows.	
		r 1		S	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None		
3	Royalties or licenses		None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ NoneTelaDoc Health, DynaMed, and Astra	Consulting to self
		Zeneca	
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	TelaDoc Health, DynaMed, and Astra Zeneca	Honoraria to self
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	□ None Bristol-Myers Squibb, Novocure, and Abbvie/Stemcentrx	Institutional research support
Plea [⊠]	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Da	te:	5/10/2023		
You	ur Name:	Susumu Kobayashi		
Ma	Manuscript Title: [EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review o approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates			
Ma	Manuscript Number (if known): TLCR-23-98			
cor affe ind	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if			
		tioned in the manuscript.		
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			
		lame all entities with whom you have this elationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere	
			ere	
1		elationship or indicate none (add rows as needed) made to you or to your institution)	ere	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	elationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work None	ere	

03/15/2023

Research support outside submitted work

ICMJE Disclosure Form

Royalties to self and institution

R01 CA240257

Boehringer Ingelheim, MiRXES,

Johnson&Johnson, and Taiho

National Cancer Institute/NIH

Therapeutics

Life Technologies

□ None

contracts from any entity (if not

indicated in item

#1 above).

Royalties or

licenses

3

1

			s/Comments (e.g., if payments were or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Chugai Pharmaceutical, and Takeda Pharmaceuticals	self
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	[⊠] None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date: <u>5/10/2023</u>
Your Name: Paul VanderLaan MD, PhD
Manuscript Title: EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approved
targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Manuscript number (if known): TLCR-23-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	None	Gala Therapeutics, Galvanize Therapeutics, Ruby Robotics, Intuitive Surgical: all consulting fees paid to

			me, all unrelated to the content of the submitted manuscript
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	Editor-in-Chief, Journal of the American Society of Cytopathology
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	_XNone	

PVL has received consulting fees for pathology services for Gala Therapeutics, Galvanize Therapeutics, Intuitive Surgical, and Ruby Robotics; all unrelated to the content of the current manuscript.

PVL is Editor-in-Chief of the Journal of the American Society of Cytopathology.

Please place an "X" next to the following statement to indicate your agreement:

Date:	5/10/2023	
Your Name:	Daniel B Costa	
Manuscript Title:	EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates	
Manuscript Number (if known):	TLCR-23-98	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this Specifications/Comments (e.g., if payments were		
		relationship or indicate none (add rows as needed)	· · · · · · · · · · · · · · · · · · ·	
		Time frame: Since the initial planning of the work		
pres mar fund of s med artic cha No	support for the esent anuscript (e.g., nding, provision study materials, edical writing, icle processing arges, etc.) time limit for s item.		Click the tab key to add additional rows.	
2 6.		Time frame: past 36 months	5	
	rants or ontracts from	□ None		
	ny entity (if not dicated in item	National Cancer Institute/NIH	R37 CA218707	
	1 above).			
	oyalties or censes	□ None		
ПСС	.eiises	1 .	Royalties to self and institution (outside submitted work)	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Blueprint Medicines, and Janssen	Consulting to self
		Teladoc and Grand Rounds by Included Health	Consulting to self
	Daymantan		
5	honoraria for		
	lectures, presentations, speakers bureaus,	Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Blueprint Medicines, and Janssen	Honoraria to self
	manuscript writing or		
	educational events		
6	Payment for expert testimony		
7	attending		
	meetings and/or travel		
8	Patents planned, issued or	[⊠] None	
	pending		
9	Participation on a Data Safety None		
	Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	None	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Merck Sharp and Dohme, Merrimack Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals, Tesaro and Daiichi Sankyo	Institutional research support	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				